Skip to main content
    N

    Novavax Inc (NVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.82
    +0.18 (+1.42%)

    Market Cap: $2.08B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -3.97%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.16
    Range$-0.47 - $0.50
    8 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.02-639.3%
    60d ago$-0.18+7.9%
    30d ago$-0.18+7.9%
    7d ago$-0.18+7.9%
    Current$-0.16
    Revenue Consensus
    $87M
    Range$33M - $179M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.19
    Range$-0.55 - $1.25
    9 analysts
    Revenue Consensus
    $165M
    Range$41M - $287M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.19---
    Sep 26EST
    		-$-0.16---
    Jun 26
    Reported Aug 6
    		$-0.32$-0.36+11.11%Beat-151.6%
    Mar 26
    Reported May 6
    		$-0.06N/A+83.78%Beat-102.0%
    Dec 25
    Reported Feb 26
    		$0.11N/A+116.67%Beat+121.2%
    Sep 25
    Reported Nov 6
    		$-0.47N/A+58.41%Beat+38.2%
    Jun 25
    Reported Aug 6
    		$0.62$0.06+933.33%Beat-37.4%
    Mar 25
    Reported May 8
    		$2.93$0.71+312.68%Beat+379.0%
    Dec 24
    Reported Feb 27
    		$-0.52$-0.51-1.21%Miss+63.9%
    Sep 24
    Reported Nov 12
    		$-0.76$-0.75-1.33%Miss+39.7%
    Jun 24
    Reported Aug 8
    		$0.99$1.70-41.76%Miss+70.7%
    Mar 24
    Reported May 10
    		$-1.05$-1.06+0.94%Beat+69.2%
    Dec 23
    Reported Feb 28
    		$-1.44$-0.35-311.43%Miss+36.8%
    Sep 23
    Reported Nov 9
    		$-1.26$-2.21+42.99%Beat+41.4%
    Jun 23
    Reported Aug 8
    		$0.58$-1.16+150.00%Beat+108.9%
    Mar 23
    Reported May 9
    		$-3.41$-3.46+1.45%Beat-233.2%
    Dec 22
    Reported Feb 28
    		$-2.28$-1.05-117.14%Miss+79.6%
    Sep 22
    Reported Nov 8
    		$-2.15$1.59-235.22%Miss+50.1%
    Jun 22
    Reported Aug 8
    		$-6.53$5.18-226.06%Miss-37.5%
    Mar 22
    Reported May 9
    		$2.56$2.65-3.40%Miss+183.9%
    Dec 21
    Reported Feb 28
    		$-11.18$-1.80-521.11%Miss-314.1%
    Sep 21
    Reported Nov 4
    		$-4.31$-3.55-21.41%Miss-34.3%
    Jun 21
    Reported Aug 5
    		$-4.75$-3.25-46.15%Miss-1483.3%
    Mar 21
    Reported May 10
    		$-3.05$-3.60+15.28%Beat-425.9%
    Dec 20
    Reported Mar 1
    		$-2.70$-1.49-81.21%Miss-138.9%
    Sep 20
    Reported Nov 9
    		$-3.21$1.73-285.55%Miss-189.2%
    Jun 20
    Reported Aug 10
    		$-0.30$-0.33+9.09%Beat+82.2%
    Mar 20
    Reported May 11
    		$-0.58$-0.67+13.43%Beat+73.6%
    Dec 19
    Reported Mar 11
    		$-1.13$-1.06-6.60%Miss+56.5%
    Sep 19
    Reported Nov 7
    		$-1.11$-0.89-24.72%Miss+53.8%
    Jun 19
    Reported Aug 7
    		$-1.69$-1.59-6.29%Miss+29.6%
    Mar 19
    Reported May 2
    		$-2.20$-2.26+2.65%Beat+21.4%
    Dec 18
    Reported Mar 18
    		$-2.60$-2.60+0.00%Beat+18.8%
    Sep 18
    Reported Nov 7
    		$-2.40$-2.52+4.76%Beat+20.0%
    Jun 18
    Reported Aug 8
    		$-2.40$-2.46+2.44%Beat+25.0%
    Mar 18
    Reported May 9
    		$-2.80$-2.78-0.72%Miss+12.5%
    Dec 17
    Reported Mar 14
    		$-3.20$-3.09-3.56%Miss+23.8%
    Sep 17
    Reported Nov 7
    		$-3.00$-3.19+5.96%Beat-
    Jun 17
    Reported Aug 8
    		$-3.20$-3.17-0.95%Miss-
    Mar 17
    Reported May 8
    		$-3.20$-3.47+7.78%Beat-
    Dec 16
    Reported Feb 27
    		$-4.20$-4.58+8.30%Beat-

    Key Metrics

    Valuation
    P/E Ratio-17.32EV/EBITDAN/A
    Price/FCF-49.04xFCF Yield-2.04%
    Profitability
    Profit Margin-59.90%Operating Margin-89.60%
    ROE-898.00%ROIC-193.19%
    Financial Health
    Debt/Equity-1.53xInterest Coverage9.63x
    Current Ratio2.33xQuick Ratio2.30x
    Trading Statistics
    Beta2.44Avg Volume8.43M
    52-Week High$13.3952-Week Low$6.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.03
    SMA 20$11.32
    SMA 50$9.95
    SMA 200$9.13
    EMA 10$12.11
    EMA 20$11.46
    EMA 50$10.39
    EMA 200$9.13

    MACD

    Line: 0.79Signal: 0.66Hist: 0.13

    ADX

    ADX: 57.7+DI: 32.0-DI: 6.8

    Aroon & PSAR

    Aroon Up68.0
    Aroon DownN/A
    PSAR$10.81

    Bollinger Bands

    Upper Band$13.26
    Lower Band$9.38
    %B Position3428%(Upper)
    Band Width0.89

    RSI (14-Day)

    Neutral
    67.0

    Momentum Oscillators

    Stoch %K80.0
    Stoch %D79.3
    Williams %R-18.1
    ROC (10d)20.9%
    Momentum2.22
    CCI (20d)120.7
    MFI (14d)65.0

    Volatility Measures

    ATR (14d)$0.91(7.1%)
    StdDev (20d)0.97
    Hist Vol100.5%(High)

    Volume Flow

    VWAP$12.75
    OBV161.0M
    AD Line-112.6M
    CMF (20d)0.114

    Volume Metrics

    Avg Vol (20d)8.7M
    Vol Ratio0.8x
    VWMA (20d)$11.67

    Pivot Points

    R3$13.90
    R2$13.62
    R1$13.13
    Pivot Point$12.85
    S1$12.36
    S2$12.08
    S3$11.59

    Advanced Oscillators

    TSI30.92
    Ultimate Osc57.0
    KST244.73

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$56.70M$139.51M$147.14M$70.44M$239.24M$666.65M$88.31M$84.51M$415.48M$93.86M$291.34M$186.99M
    Cost of Revenue$14.25M$30.70M$22.10M$21.50M$15.32M$14.12M$36.67M$60.62M$46.24M$59.21M$154.98M$98.93M
    Gross Profit$42.45M$108.82M$125.03M$48.95M$223.91M$652.54M$51.64M$23.89M$369.24M$34.65M$136.37M$88.06M
    Operating Expenses$97.36M$124.25M$110.81M$226.97M$122.84M$137.03M$182.72M$157.91M$208.24M$179.48M$319.93M$213.69M
    R&D$70.69M$95.47M$75.88M$98.27M$79.23M$88.94M$104.38M$87.16M$106.95M$92.68M$164.70M$106.23M
    SG&A$26.66M$28.78M$34.12M$31.66M$43.61M$48.09M$78.34M$70.75M$101.30M$86.80M$155.24M$107.46M
    Operating Income$-54,906,000$-15,430,000$14.23M$-178,018,000$101.07M$515.51M$-131,080,000$-134,018,000$161.00M$-144,831,000$-183,568,000$-125,632,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$5.69M$4.90M$5.82M$34.20M$5.52M$5.72M$7.58M$4.24M$4.14M$4.11M$4.12M$2.86M
    Income Before Tax$-51,676,000$-8,506,000$17.90M$-203,036,000$107.45M$519.85M$-73,581,000$-122,332,000$164.59M$-145,288,000$-176,701,000$-131,473,000
    Income Tax Expense$1.71M$985,000$376,000$-657,000$946,000$1.20M$7.45M$-1,032,000$2.21M$2.26M$1.69M$-697,000
    Net Income$-53,387,000$-9,491,000$17.53M$-202,379,000$106.51M$518.65M$-81,030,000$-121,300,000$162.38M$-147,550,000$-178,389,000$-130,776,000
    EBITDA$-42,931,000$-543,000$28.85M$-162,255,000$120.53M$533.91M$-53,479,000$-105,396,000$179.86M$-129,030,000$-161,790,000$-117,293,000
    EBIT$-45,987,000$-3,605,000$23.73M$-168,840,000$112.97M$525.57M$-65,996,000$-118,096,000$168.73M$-141,177,000$-172,584,000$-128,614,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NVAX

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    100.0%
    Active Awards
    0
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Novavax, Inc. Stock 12‑Month Price Target Raised to $15, Implies 19% Upside

    Novavax, Inc.'s average 12-month stock price target has been increased from $14.86 to $15 by 7 analysts, with individual forecasts ranging from $8 to $25 per share. This updated target suggests a potential upside...

    TradingView•10/15/26•Bullish

    Novavax Inc. stock outperforms competitors on strong trading day

    Novavax Inc. (NVAX) shares rose 1.42% to $12.82, outperforming the broader market despite a favorable trading session where the NASDAQ Composite Index and Dow Jones Industrial Average also saw gains. The stock closed...

    MarketWatch•10/15/26•Bullish

    Lobbying Update: $120,000 of NOVAVAX INC lobbying was just disclosed

    Novavax Inc. recently disclosed $120,000 in lobbying expenditures for Q3 2026, focusing on federal vaccine programs and regulatory frameworks. The article also details significant hedge fund activity in NVAX stock...

    Quiver Quantitative•10/14/26•Neutral

    Novavax Inc. stock outperforms competitors on strong trading day

    Novavax Inc. (NVAX) saw its stock advance 1.26% to $12.82 on a trading day where the broader market, including the NASDAQ Composite Index and Dow Jones Industrial Average...

    MarketWatch•10/13/26•Bullish

    Novavax Inc (Coinbase Tokenized Stock) to Chinese Yuan Price Today | Live NVAXc to CNY Converter & Exchange Rate | CryptoRank.io

    This article provides a detailed overview of Novavax Inc (Coinbase Tokenized Stock) (NVAXc) in relation to the Chinese Yuan (CNY). It notes that there is currently no available exchange rate for NVAXc to CNY...

    CryptoRank•10/13/26•Neutral

    NVAX Valuation and Fair Value

    P/E
    -17.3x
    Forward P/E
    2.6x
    P/FCF
    -49.0x
    PEG
    1.3x
    P/B
    -11.1x
    See GNG's fair value

    NVAX Profitability: Margins, ROIC and FCF

    Gross margin
    78.6%
    Operating margin
    -89.6%
    Net margin
    -59.9%
    ROIC
    -193.2%
    ROE
    -898.0%
    FCF margin
    -10.4%
    FCF yield
    -2.0%

    NVAX Competitors

    CompanyTicker
    Avadel Pharmaceuticals PLCAVDL
    BioCryst Pharmaceuticals IncBCRX
    Pharvaris BVPHVS
    Viridian Therapeutics IncVRDN
    Dynavax Technologies CorporationDVAX
    Vericel Corp OrdVCEL
    Progyny IncPGNY
    GeneDx Holdings Corp.WGS

    Sector: Healthcare

    NVAX Analyst Ratings

    Consensus
    Hold
    Analysts
    9
    Strong Buy
    0
    Buy
    5
    Hold
    1
    Sell
    1
    Strong Sell
    2

    NVAX Bull Case vs Bear Case

    Bull case

    • NVAX beat EPS estimates in 75.0% of its last 8 reported quarters.

    Bear case

    • NVAX has a -59.9% net profit margin.
    • NVAX's quarterly revenue changed -76.3% year over year.
    • 33.3% of NVAX's analyst ratings are Sell or Strong Sell.

    NVAX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    189.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.16
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About NVAX

    Does NVAX pay dividends?

    Novavax Inc (NVAX) does not currently pay a regular dividend.

    What is NVAX's market cap?

    Novavax Inc (NVAX) has a market capitalization of $2.08B with a current stock price of $12.82.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In